Group 1: Control Changes in Companies - Qidi Pharmaceutical's control has changed from Qidi Kefu to Hunan Sailoxian, with Jiang Xin as the actual controller, marking the sixth name change since its listing [1][2][3] - Mengke Pharmaceutical will undergo a control change as it issues 164 million shares to Hainan Whale Pharmaceutical, making Hainan Whale the controlling shareholder with a 20% stake [1][6] Group 2: Financial and Operational Implications - The control change at Qidi Pharmaceutical was triggered by a financial dispute leading to the auction of 58.607 million shares for 1.007 billion yuan [2] - Mengke Pharmaceutical plans to raise up to 1.033 billion yuan through a private placement to enhance its financial strength and support R&D efforts [6][7] - Mengke Pharmaceutical's sales revenue growth rates for 2022-2023 and 2023-2024 were 88.31% and 43.51%, respectively, with a 10.26% increase in the first half of 2025 [6][7] Group 3: Strategic Directions and Future Plans - Qidi Pharmaceutical aims to leverage new shareholder resources for business focus and operational stability amid industry changes [1] - Mengke Pharmaceutical intends to enhance its commercial efficiency and production capabilities through external partnerships and funding [7][8] - The strategic agreement signed between Hengyang Municipal Government and Hengchang Pharmaceutical may further drive operational development for Qidi Pharmaceutical [5]

Market Overview - The short-term index is expected to maintain an upward trend after a period of consolidation and profit-taking [1][15] - The US stock market experienced declines for two consecutive trading days, with the Dow Jones down 0.37%, Nasdaq down 0.33%, and S&P 500 down 0.28% [4] - Notable tech stocks showed mixed performance, with Tesla up 4.0% and Amazon down 0.2% [4] Economic Data - In August, new home sales in the US increased to an annualized total of 800,000 units, up 20.5% from July's 664,000 units, exceeding market expectations [4] - International oil prices reached a seven-week high, with WTI crude oil rising 2.49% to $64.99 per barrel and Brent crude oil increasing 2.48% to $69.31 per barrel [4] - Gold prices fell from record highs, with COMEX gold futures for September delivery down 1.28% to $3,732.10 per ounce [4] Policy Developments - The Ministry of Commerce and eight other departments issued guidelines to promote digital consumption, focusing on supply-demand coordination and proposing 14 specific measures [5] - A set of 13 policy measures to support service exports was announced, including the development of international data service businesses and the facilitation of cross-border data flow [6] Industry Insights - The Ministry of Industry and Information Technology released a work plan for the building materials industry, aiming for recovery and growth in profitability from 2025 to 2026, with a target of over 300 billion yuan in revenue from green building materials by 2026 [7] - A public consultation was initiated regarding mandatory national standards for automotive door handles, emphasizing safety and accessibility [8] Company Announcements - Wanhua Chemical expects a net profit increase of 69.81% to 109.77% year-on-year for the first three quarters of 2025, driven by strategic sales adjustments and increased exports [10] - Sinopec Oilfield Services signed a contract worth $359 million for a project in Iraq, expected to contribute 3.15% to the company's 2024 revenue [11] - Mengke Pharmaceutical's major shareholder opposed a proposed stock issuance plan that would lead to a change in control [12] - Shanghai Zhiyuan Hengyue plans to acquire 37% of Shangwei New Materials at a price of 7.78 yuan per share, with a total funding requirement of 1.16 billion yuan [13] - China Jushi announced a share repurchase plan not exceeding 400 million shares, with a total amount of up to 880 million yuan [14]

盟科药业(688373.SH)发布公告，公司股东Genie Pharma在2025年9月24日提出临时提案，提请在2025年 第二次临时股东大会增加关于罢免ZHENGYU YUAN(袁征宇)、李峙乐、吴潘成公司第二届董事会董事 职务的议案，以及选举杨宗凡、王勇、徐宇超为公司第二届董事会董事的议案。此次股东大会原定于 2025年10月9日召开，增加临时提案后，审议议案包括原议案和新增的董事罢免及选举议案。 ...

智通财经APP讯，盟科药业(688373.SH)发布公告，公司股东Genie Pharma在2025年9月24日提出临时提 案，提请在2025年第二次临时股东大会增加关于罢免ZHENGYU YUAN(袁征宇)、李峙乐、吴潘成公司 第二届董事会董事职务的议案，以及选举杨宗凡、王勇、徐宇超为公司第二届董事会董事的议案。此次 股东大会原定于2025年10月9日召开，增加临时提案后，审议议案包括原议案和新增的董事罢免及选举 议案。 ...

盟科药业(688373.SH)发布公告，公司股东Genie Pharma对公司2025年第二次临时股东大会所审议多项议 案均投反对票。Genie Pharma合计持有公司股份数量7157.28万股，占公司股份总数的10.92%。征集投 票权的起止时间为2025年9月25日至2025年10月6日。征集人反对原因包括海鲸药业参与定增资金存在不 确定性、销售渠道和人员混同风险、募投项目进度不及预期、利用海鲸药业产能提升盈利能力不确定性 以及研发领域协同效应小等。 ...

智通财经APP讯，盟科药业(688373.SH)发布公告，公司股东Genie Pharma对公司2025年第二次临时股东 大会所审议多项议案均投反对票。Genie Pharma合计持有公司股份数量7157.28万股，占公司股份总数的 10.92%。征集投票权的起止时间为2025年9月25日至2025年10月6日。征集人反对原因包括海鲸药业参 与定增资金存在不确定性、销售渠道和人员混同风险、募投项目进度不及预期、利用海鲸药业产能提升 盈利能力不确定性以及研发领域协同效应小等。 ...

Core Points - Genie's Pharma, the largest shareholder of Amgen Pharmaceutical, holds 71.57 million shares, accounting for 10.92% of the total shares [1] - Genie Pharma opposes several proposals at the upcoming extraordinary general meeting, including a plan for Amgen to issue shares to HaiJing Pharmaceutical to raise up to 1.033 billion yuan [1] - If the share issuance is completed, HaiJing Pharmaceutical will hold 20% of Amgen's shares and nominate 5 out of 9 board members, making it the controlling shareholder [1] Proposal Details - The proposal involves Amgen raising funds through a specific share issuance plan, which has raised concerns from Genie Pharma [1] - Genie Pharma's objections include uncertainties regarding the funding from HaiJing Pharmaceutical, potential loss of independence for Amgen, and doubts about the synergy in research and development [1] - Concerns are also raised about HaiJing Pharmaceutical's compliance history and management capabilities, which could impact Amgen's operations [1]

上海盟科药业股份有限公司 2025 年第二次临时股东大会 会议资料 二 O 二五年十月 上海盟科药业股份有限公司 2025 年第二次临时股东大会会议资料 证券代码：688373 证券简称：盟科药业 | 2025 年第二次临时股东大会会议议程 5 | | | --- | --- | | 议案一 | 8 | | 关于公司符合向特定对象发行股票条件的议案 | 8 | | 议案二 | 9 | | 关于公司向特定对象发行股票方案的议案 | 9 | | 议案三 | 12 | | 关于公司向特定对象发行股票预案的议案 | 12 | | 议案四 | 13 | | 关于公司向特定对象发行股票方案论证分析报告的议案 | 13 | | 议案五 | 14 | | 关于公司向特定对象发行股票募集资金使用可行性分析报告的议案 14 | | | 议案六 | 15 | | 关于公司引入战略投资者并签署《战略合作协议》的议案 | 15 | | 议案七 | 16 | | 关于签署《附条件生效的向特定对象发行股份认购协议》的议案 16 | | | 议案八 | 17 | | 关于公司向特定对象发行股票涉及关联交易事项的议案 | 17 | | 议案九 ...

证券代码：688373 证券简称：盟科药业 公告编号：2025-052 上海盟科药业股份有限公司 关于2025年第二次临时股东大会增加临时提案暨补 充通知的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 股东大会有关情况 1. 股东大会的类型和届次： 2025年第二次临时股东大会 | 股份类别 | 股票代码 | 股票简称 | 股权登记日 | | --- | --- | --- | --- | | 股 A | 688373 | 盟科药业 | 2025/9/24 | 二、 增加临时提案的情况说明 公司已于2025 年 9 月 23 日公告了股东大会召开通知，单独或者合计持有 10.92%股份的股东Genie Pharma，在2025 年 9 月 24 日提出临时提案并书面提交 股东大会召集人。股东大会召集人按照《上海证券交易所科创板上市公司自律监 2. 股东大会召开日期：2025 年 10 月 9 日 3. 股东大会股权登记日： 1. 提案人：Genie Pharma 2. 提案程序说明 管指引第 1 号 — 规范运 ...

公司及董事会全体成员保证公告内容与 Genie Pharma 提供的信息一致。 证券代码：688373 证券简称：盟科药业 公告编号：2025-051 上海盟科药业股份有限公司 关于股东 Genie Pharma 公开征集投票权的公告 股东 Genie Pharma 保证向公司提供的信息内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其真实性、准确性和完整性依法承担法律责任。 重要内容提示： 按照《中华人民共和国证券法》《上市公司股东会规则》《公开征集上市公 司股东权利管理暂行规定》《上海盟科药业股份有限公司章程》或其他有关规定， 持有上市公司1%以上有表决权股份的股东Genie Pharma作为征集人，就公司拟于 1 征集投票权的起止时间：2025年9月25日至2025年10月6日 Genie Pharma（以下简称"征集人"）对上海盟科药业股份有限公司（以下简 称"公司"或"上市公司"）2025年第二次临时股东大会所审议议案除议案9 外均投反对票； 截至征集公告披露日，征集人Genie Pharma合计持有公司股份数量71,572,817 股，均为有表决权股份，占公司股份总数的10.92%； 征集人 ...